In May 2024, Vect-Horus, a biotechnology company based in Marseille, France, will participate in the Viva Technology conference in Paris. The company specializes in designing molecular vectors that help deliver therapeutic molecules and imaging agents to specific tissues.
Vect-Horus has been selected as one of the 10 start-ups showcasing disruptive technologies at the event by France’s National Center for Scientific Research (CNRS). At the conference, the company will present its VECTrans® technology, which is a groundbreaking innovation in drug targeting to the brain and other pathological tissues such as cancer.
During the conference, Vect-Horus Chief Scientific Officer Jean-Manuel Pean will participate in a roundtable discussion to provide an overview of the company’s pipeline and recent advancements in its technology. He will also discuss progress made on optimizing the VECTrans® technology, early clinical trials of theragnostic agents for glioblastoma and pancreatic cancer, and updates on partnerships with companies like Novo Nordisk and Ionis Pharmaceuticals.
Further details about the roundtable program will be announced closer to the event. Founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP), UMR7051, CNRS, and Aix Marseille University, Vect-Horus focuses on developing vectors for targeting and delivering therapeutic and imaging agents to organs and tumors. The company employs 38 individuals primarily in research and development. For more information about Vect-Horus visit their website at www.vect-horus.com or contact them at contact@vect-horus.com
